Genpact (NYSE:G - Get Free Report) had its price target hoisted by equities researchers at JPMorgan Chase & Co. from $40.00 to $45.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has a "neutral" rating on the business services provider's stock. JPMorgan Chase & Co.'s price objective points to a potential upside of 31.74% from the company's previous close.
G has been the topic of several other reports. Deutsche Bank Aktiengesellschaft set a $31.00 target price on Genpact in a research note on Friday, July 10th. BMO Capital Markets reaffirmed a "market perform" rating and set a $40.00 target price on shares of Genpact in a research note on Friday. Robert W. Baird lowered their price objective on Genpact from $45.00 to $38.00 and set a "neutral" rating for the company in a research note on Tuesday, July 7th. Mizuho cut their target price on Genpact from $49.00 to $39.00 and set a "neutral" rating on the stock in a research note on Monday, May 11th. Finally, TD Cowen restated a "buy" rating on shares of Genpact in a report on Friday. Two analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $39.11.
View Our Latest Report on G
Genpact Trading Down 5.5%
Shares of Genpact stock traded down $2.00 during trading hours on Friday, hitting $34.16. The company's stock had a trading volume of 1,226,964 shares, compared to its average volume of 2,501,802. Genpact has a 12 month low of $26.85 and a 12 month high of $48.64. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.69 and a quick ratio of 1.69. The company has a market capitalization of $5.79 billion, a PE ratio of 10.51, a price-to-earnings-growth ratio of 1.00 and a beta of 0.57. The stock has a 50 day moving average of $31.20 and a 200 day moving average of $35.22.
Genpact (NYSE:G - Get Free Report) last posted its quarterly earnings data on Tuesday, June 30th. The business services provider reported $1.00 earnings per share (EPS) for the quarter. Genpact had a return on equity of 22.70% and a net margin of 11.04%.The business had revenue of $1.34 billion during the quarter. Analysts predict that Genpact will post 3.64 earnings per share for the current year.
Institutional Trading of Genpact
A number of institutional investors and hedge funds have recently modified their holdings of the business. Osbon Capital Management LLC purchased a new stake in shares of Genpact during the fourth quarter valued at $25,000. iSAM Funds UK Ltd purchased a new position in Genpact in the 3rd quarter worth about $29,000. Johnson Financial Group Inc. bought a new position in Genpact during the 3rd quarter valued at about $29,000. V Square Quantitative Management LLC purchased a new stake in shares of Genpact during the 4th quarter valued at about $30,000. Finally, Larson Financial Group LLC boosted its holdings in shares of Genpact by 428.4% during the 4th quarter. Larson Financial Group LLC now owns 708 shares of the business services provider's stock valued at $33,000 after acquiring an additional 574 shares during the last quarter. Institutional investors own 96.03% of the company's stock.
Key Headlines Impacting Genpact
Here are the key news stories impacting Genpact this week:
- Positive Sentiment: Genpact reported second-quarter EPS of $1.00, exceeding the $0.97 analyst consensus and rising from $0.88 a year earlier. Revenue increased 7.1% year over year to $1.34 billion, also topping estimates. Advanced Technology Solutions revenue growth of 24% was a key performance driver. Genpact Reports Second Quarter 2026 Results
- Positive Sentiment: The company raised its fiscal 2026 EPS guidance to approximately $4.09, above the $3.99 consensus estimate. Third-quarter EPS guidance of $1.04-$1.05 also exceeded the $1.03 consensus, while revenue guidance was broadly in line with expectations.
- Positive Sentiment: Needham maintained a “buy” rating despite reducing its price target to $45 from $50, implying substantial potential appreciation from recent trading levels. Benzinga analyst action
- Neutral Sentiment: Susquehanna raised its price target to $37 from $33 but kept a “neutral” rating, signaling modest upside while maintaining a cautious stance. Benzinga analyst action
- Neutral Sentiment: Brokerages currently have a consensus “hold” recommendation, which may limit the market’s reaction to the earnings beat and higher guidance. Genpact broker consensus
- Negative Sentiment: Although Needham remains bullish, its $5 reduction in the price target and Susquehanna’s neutral rating may be weighing on sentiment. The stock is also trading below its 200-day moving average, reflecting lingering investor caution.
Genpact Company Profile
(
Get Free Report)
Genpact is a global professional services firm specializing in digitally powered business process management and services. The company partners with clients across industries to design, transform and run key operations, leveraging data analytics, artificial intelligence, automation and domain expertise. Its offerings span finance and accounting, supply chain management, procurement, customer experience, risk and compliance, and other critical business functions.
Founded in 1997 as the business process outsourcing arm of General Electric and originally known as GE Capital International Services, the company rebranded as Genpact in 2005 and completed its initial public offering on the New York Stock Exchange in 2007 under the ticker symbol “G.” Over time, Genpact has expanded beyond traditional outsourcing to focus on digital transformation and innovation, helping organizations accelerate growth and improve operational efficiency.
Headquartered in New York City, Genpact serves clients in more than 30 countries across North America, Latin America, Europe and Asia Pacific.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Genpact, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genpact wasn't on the list.
While Genpact currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.